OncoHost, a technology company transforming the approach to precision medicine for improved patient outcomes, today announced that Ron Andrews has joined the company as Strategic Consultant to the CEO ...

1|3600|VA687C00008|DEPARTMENT OF VETERANS AFFAIRS |36|0|BPA CALL|A|1|0|2.19e+05|00|VETERANS AFFAIRS, DEPARTMENT OF |A|260-NETWORK CONTRACT OFFICE 20 |WA|36 ...

Separately, Roche's chief medical officer and head of global product development Levi Garraway, has been appointed to an enlarged corporate ... and a 3% increase for diagnostics to CHF 17.7 ...

To determine the type and severity of a cancer, pathologists typically analyze thin slices of a tumor biopsy under a ...

Dr. Alexander brings two decades of biotechnology, biopharma, and medical leadership, most recently as SVP, Research & Development and Head of Boston Roche Innovation Center ... Brett Blackman is ...

Adaptimmune’s Phase II IGNYTE-ESO trial investigating experimental T cell therapy lete-cel has achieved its primary endpoint.

The immunohistochemistry test detects the folate receptor 1 protein, which is over-expressed in most ovarian cancers.

Swiss drug major Roche Group (RHHBY) announced Monday that it has received CE Mark for its VENTANA FOLR1 (FOLR1-2.1) RxDx Assay, ...

CNW/ - Hoffmann-La Roche Limited (Roche Canada) is pleased to announce, with support from the Government of Ontario through ...

Roche has secured CE mark approval for its immunohistochemistry (IHC) companion diagnostic test, VENTANA FOLR1 (FOLR1-2.1) ...